---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-018591"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T09:11:40.452519+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaxart doses first patient in 10,000-subject Phase 2b oral COVID-19 vaccine trial against mRNA comparator

## Summary
- First patient dosed in 10,000-participant portion of Phase 2b trial for oral pill COVID-19 vaccine candidate.
- Trial to assess relative efficacy, safety, and immunogenicity versus approved mRNA COVID-19 vaccine over 12 months.
- DSMB reviewed 400-participant sentinel cohort safety data and recommended study proceed without modifications.
- Project funded by BARDA/NIAID under Project NextGen with award valued up to $460.7 million.

## SEC filing metadata
- accession: 0001437749-25-018591
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925018591/0001437749-25-018591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925018591/vxrt20250527_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-018591
- JSON: https://secwatch.observer/filing/0001437749-25-018591.json
- Plain text: https://secwatch.observer/filing/0001437749-25-018591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.